White Paper

The Pivotal Role of Packaging in Patient Safety

Why the integrity of primary packaging for injectable drugs is inseparable from patient safety — and how manufacturing excellence is the foundation of both.

Status Published

Format White Paper

Language English

Access Registration Required

Access the White Paper

Resource Overview

About this White Paper

For injectable drug products, primary packaging is not merely a container — it is an active safety system. Unlike oral drugs, injectables bypass the body's natural filtration mechanisms entirely, meaning any contamination introduced through the container closure system enters the bloodstream directly. This 2022 report by Datwyler examines the full spectrum of patient safety risks associated with parenteral packaging, including container closure integrity (CCI) failures, extractables and leachables (E&L) interactions with sensitive biologics, visible and sub-visible particulate contamination, and the self-sealing performance of multi-dose elastomeric closures.

The report highlights the growing importance of home care drug delivery — prefilled syringes and autoinjectors — where packaging must maintain integrity outside the controlled hospital environment. It then outlines how Datwyler's FirstLine® manufacturing standard directly addresses these risks through ISO 5 cleanroom environments, 100% automated camera inspection, metal detection, a zero-defect design philosophy, and fluoropolymer-coated components including OmniFlex® stoppers and NeoFlex™ plungers. The report also covers material selection considerations — elastomer geometry, sterilization compatibility, silicone oil avoidance — positioning Datwyler as a quality-by-design partner for pharmaceutical and biotech companies seeking to protect patients and reduce recall risk.

Container closure integrity (CCI) is the overriding patient safety priority in parenteral packaging — failures can lead to drug degradation, incorrect dosing, or direct contamination of a patient's bloodstream, with consequences that are especially severe for self-administered biologics in home care settings.
Extractables and leachables (E&L) from elastomeric closures pose a direct risk to sensitive biologic drugs, potentially causing protein denaturation, loss of efficacy, or adverse patient reactions — making elastomer compound selection and coating strategy critical decisions in packaging development.
Datwyler's FirstLine® manufacturing standard — featuring ISO 5 cleanrooms, 100% automated camera and metal detection inspection, paperless production, and fluoropolymer-coated OmniFlex® and NeoFlex™ components — is purpose-built to deliver the lowest achievable contamination and defect levels for high-risk injectable drug applications.

The Pivotal Role of Packaging in Patient Safety

About this White Paper

Download the White Paper

More Patient Safety Resources

Precision Protection for High‑Performance Aesthetic Injectables

Healthcare Shake-Up: How the Latest Innovations Are Making Meds Safer and Eco-Friendly!

Packaging with Purpose: Engineering Safety for Every Dose

Stay informed on Datwyler Healthcare technical resources